Immunization of alpacas with HIV 1 ENV trimers to develop broadly neutralizing nanobodies targeting CD4 biding site
Ended Purchase Order Awarded Last action
- Contract number
- 75N93023P01111
- Awardee
-
Capralogics Inc. UEI C1AJXN3ARJJ3
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $160,920
Award facts
- Opportunity
-
- Immunization of Alpacas with HIV-1 Env Trimers to Develop Broadly Neutralizing Nanobodies Targeting CD4 Binding Site Pre-Solicitation · NOINIAID232182229 · Posted Aug 8, 2023
- Contract value 82% obligated
-
- $160,920.00 Current, with exercised options
- $195,570.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Gilbertville, Hardwick, MA, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$3,000 | |
| Exercise an Option | $3,000 | |
| Original award | $160,920 |
About this award
The National Institute of Allergy and Infectious Diseases awarded a $195,570 firm fixed-price purchase order to Capralogics Inc., a specialized polyclonal antibody production facility based in Gilbertville, Massachusetts, to conduct an animal immunization study continuing research initiated in 2007. Under this non-competitive contract, Capralogics will immunize alpacas with HIV-1 envelope trimers, perform immunizations and blood screenings according to protocol, and collect, isolate, store, and ship peripheral blood mononuclear cells to support the development of broadly neutralizing nanobodies targeting the virus's CD4 binding site. The contract was awarded on August 25, 2023, with an ultimate completion date of August 24, 2024, with no subcontractors identified or set-aside designations applied.
Capralogics' expertise in animal-based antibody development made it well-suited for this continuation effort, leveraging over 29 years of experience providing high-quality animal serum and cellular products to the diagnostic, pharmaceutical, and research sectors. NIAID's investment in this research supports the agency's broader mission to develop novel immunological approaches to infectious diseases, particularly HIV, by utilizing camelid species such as alpacas, which naturally produce unique antibody structures known as nanobodies that have shown promise as therapeutic candidates.
Quick answers
Who was awarded contract 75N93023P01111?
75N93023P01111 was awarded to Capralogics Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 25, 2023.
How much is contract 75N93023P01111 worth?
The government has obligated $160,920 on 75N93023P01111. Its potential value, with all options, is $195,570.
Was contract 75N93023P01111 competed?
The extent of competition for 75N93023P01111 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award